Income Taxes (Details 3) (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2011	Jun. 30, 2012
Components of deferred tax assets
Net operating loss carryforwards	$ 121,937,000		$ 98,601,000
Research and development tax credit carryforwards	12,806,000		10,393,000
Property and other intangible assets	2,077,000		1,486,000
Deferred revenue	25,484,000		28,325,000
Stock-based compensation	5,759,000		3,302,000
Deferred lease incentive	4,771,000		5,100,000
Other liabilities	508,000		512,000
Total deferred tax assets	173,342,000		147,719,000
Valuation allowance	(173,342,000)		(147,719,000)
Income taxes, additional disclosures
Increase in valuation allowance	25,600,000
Minimum increase in the ownership of certain shareholders or public groups in the stock of a corporation for an ownership change as defined by Section 382 (as a percent)	50.00%
Period over which increase in ownership of certain shareholders or public groups in the stock of a corporation for an ownership change as defined by Section 382	3 years
Federal grant funding the Company was awarded under the Patient Protection and Affordable Care Act of 2010 to develop new anticancer therapies		$ 1,200,000